Pharmaleads CEO outlines pipeline of non-opiate and non-addictive products

At the recent BIO-Europe® partnering meeting, Scrip talks to Thierry Bourbié, chair and CEO of Pharmaleads, an emerging pharmaceutical company developing non-opiate and non-addictive products for the management of acute and chronic severe pain. Pharmaleads’ compounds, Dual ENKephalinase inhibitors or DENKIs, aim to protect enkephalins, a key element of the body’s natural pain management system.
The company has two DENKIs in development: PL265 for the treatment of neuropathic pain (oral) and ocular pain/dry eye syndrome (eye drops); and PL37 for the treatment of post-surgical pain as a substitute to injectable opiates. Bourbié said the firm is looking to raise around USD 20 million to fund three Phase II trials for its pipeline compounds.